Genitourinary Cancer Clinical Trial Sentiment
Hear what key opinion leaders such as Dr. Toni Choueiri, Dr. Tian Zhang, Dr. Guru Sonpavde, Dr. Andrea Apolo, Dr. Neeraj Agarwal and others are saying about the results of the most recent genitourinary cancer clinical trials.
NIAGARA - FREE ACCESS
AstraZeneca's NIAGARA trial, presented at #ESMO24, investigated the effects of adding durvalumab to the standard neoadjuvant chemotherapy (cisplatin and gemcitabine) followed by adjuvant durvalumab after cystectomy in patients with muscle-invasive bladder cancer (MIBC).
Read more
AMBASSADOR
Presented by Dr. Andrea Apolo at #GU24, AMBASSADOR is a randomized, open-label phase III trial evaluating pembrolizumab vs observation for the adjuvant treatment of localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma.
Read more
ANTICIPATE
ANTICIPATE is a phase I/II open-label, multicenter study to evaluate the safety and efficacy of oral APL-1202 in combination with tislelizumab compared to tislelizumab alone as neoadjuvant therapy in patients with muscle invasive bladder cancer. Dr. Matt Galsky presented the interim analysis of the ANTICIPATE trial at #GU24.
Read more
BRCAAway
BRCAAway is a phase II clinical trial evaluating the combination of olaparib and abiraterone in patients with metastatic castration-resistant prostrate cancer (mCRPC) harboring BRCA1/2 or ATM mutations. The trial was presented by Dr. Maha Hussain at #GU24.
Read more
CheckMate214
CheckMate 214, presented by Dr. Nizar Tannir at #GU24, is a phase III clinical trial, comparing nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.
Read more
CheckMate 914
CHECKMATE 914 is a phase III clinical trial of adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy. Dr. Robert Motzer presented the CHECKMATE 914 B data at #GU24.
Read more
CheckMate 9ER
CHECKMATE 9ER is a phase 3, randomized, open-label trial of nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. Dr. Maite Bourlon presented the 55 month follow up data from CHECKMATE 9ER at #GU24.
Read more
CONTACT-02
CONTACT-02 is a phase III, randomized, open-label study of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostrate cancer. Dr. Neeraj Agarwal presented the CONTACT-02 data set at #GU24.
Read more
EV302
EV302 is a phase III, open label, randomized trial studying enfortumab vedotin and pembrolizumab versus platinum-based chemotherapy in untreated advanced urothelial cancer. Dr. Tom Powles is the PI of EV302.
Read more
FORMULA 509
FORMULA 509 is a multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).
Read more
KEYNOTE-564
KEYNOTE-564 is a study of adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. Dr. Tom Powles and Dr. Toni Choueri lead the KEYNOTE-564 clinical trial.
Read more
LITESPARK-005
LITESPARK-005 is a phase III, open-label, randomized study of LBA88 Belzutifan versus everolimus in participants with previously treated advanced clear cell renal cell carcinoma. Dr. Tom Powles presented data from the LITESPARK-005 study at #GU24.
Read more
S1314-COXEN
S1314-COXEN is a randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer. Dr. Bishoy Faltas presented the data from S1314-COXEN at #GU24.
Read more